Key result
Growth hormone secretagogue improves LV fractional shortening to 29% vs 21% in pacing-induced HF.
Why the study?
Exogenous GH administration influences LV myocardial growth and geometry in CHF, but effects of orally active GH secretagogues on LV function and myocyte contractility in developing CHF are unclear.
Does a growth hormone secretagogue improve LV function and myocyte contractility in a pig model of developing heart failure?
Comparison
Growth hormone secretagogue (CP-424,391) treatment vs untreated pacing CHF and sham controls
Design
Randomized preclinical study
Follow-up
3 weeks
Authors
Loading...
GHS effects in porcine CHF warrant further preclinical study; leaves open any human therapeutic role.
RCT (n=28)
randomly assigned
Does a growth hormone secretagogue improve LV function and myocyte contractility in a pig model of developing heart failure?
Absolute Event Rate: 29% vs 21%
p-value: p=<0.05
An orally active growth hormone secretagogue improved LV function and myocyte contractility in a porcine model of pacing-induced heart failure.
King et al. (2001) conducted an RCT in developing congestive heart failure (n=28). GH secretagogue (CP-424,391) vs. untreated pacing CHF and sham controls was evaluated on LV fractional shortening (p=<0.05). Treatment with a growth hormone secretagogue in a pig model of developing heart failure improved LV fractional shortening (29% vs 21%, P<0.05) compared to untreated pacing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: